Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Sees Large Increase in Short Interest

Aldeyra Therapeutics, Inc (NASDAQ:ALDX) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 3,840,000 shares, an increase of 8.2% from the December 31st total of 3,550,000 shares. Based on an average daily volume of 463,300 shares, the days-to-cover ratio is presently 8.3 days.

Aldeyra Therapeutics Stock Down 1.0 %

ALDX stock traded down $0.05 during trading on Monday, reaching $5.19. 100,931 shares of the stock were exchanged, compared to its average volume of 329,520. Aldeyra Therapeutics has a twelve month low of $2.71 and a twelve month high of $6.55. The stock has a 50 day simple moving average of $5.01 and a 200-day simple moving average of $5.08. The company has a quick ratio of 6.80, a current ratio of 6.80 and a debt-to-equity ratio of 0.18.

Aldeyra Therapeutics (NASDAQ:ALDX) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.25) EPS for the quarter, hitting analysts’ consensus estimates of ($0.25). Sell-side analysts expect that Aldeyra Therapeutics will post -0.92 earnings per share for the current year.

Institutional Trading of Aldeyra Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. American Century Companies Inc. grew its holdings in shares of Aldeyra Therapeutics by 216.7% in the 2nd quarter. American Century Companies Inc. now owns 53,388 shares of the biotechnology company’s stock valued at $177,000 after buying an additional 36,528 shares during the period. The Manufacturers Life Insurance Company grew its stake in Aldeyra Therapeutics by 14.4% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 21,734 shares of the biotechnology company’s stock valued at $72,000 after buying an additional 2,729 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Aldeyra Therapeutics by 71.8% during the 3rd quarter. SG Americas Securities LLC now owns 19,543 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 8,165 shares in the last quarter. International Assets Investment Management LLC grew its position in shares of Aldeyra Therapeutics by 397.0% during the 3rd quarter. International Assets Investment Management LLC now owns 287,287 shares of the biotechnology company’s stock worth $15,480,000 after purchasing an additional 229,487 shares in the last quarter. Finally, US Bancorp DE bought a new stake in shares of Aldeyra Therapeutics during the 3rd quarter worth approximately $30,000. Institutional investors and hedge funds own 59.71% of the company’s stock.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics is a clinical-stage biotechnology company focused on the development of novel therapies with the potential to improve the lives of patients with immune-mediated diseases. Two of the company’s lead compounds, reproxalap and ADX-629, target reactive aldehyde species (RASP), which are elevated in ocular and systemic inflammatory disease, leading to elevated levels of cytokine release via activation of a broad array of inflammatory factors, including NF-κB, inflammasomes, and Scavenger Receptor A.